DHA feeding provides host protection and prevents fibrosarcoma-induced hyperlipidemia while maintaining the tumor response to araC in Fischer 344 rats.
Fischer 344 rats were inoculated with fibrosarcoma tumor cells and fed diets containing 5% or 10% (wt/wt) safflower oil or 10% oil containing docosahexaenoic acid (DHA). Animals were then treated with arabinosylcytosine (araC) or saline for six days. Tumor weights were highest in animals fed 10% safflower oil and treated with saline, intermediate in animals fed oil containing DHA and 5% safflower oil and treated with saline, and lowest in araC-treated animals from all diets. Plasma cholesterol and triglyceride levels correlated highly with final tumor size, regardless of diet or treatment group. Animals fed safflower oil had lower intestinal weights than those fed DHA, which histology demonstrated to be a result of differences in villus height and crypt depth. Substantial loss of bone marrow cells occurred in all dietary groups treated with araC; however, the proportion of granulocyte-macrophage precursors remaining in the DHA animals was higher than in saline-treated animals and twofold higher than in the animals fed 10% safflower oil and treated with araC. These data suggest that, even in the face of rapid tumor growth and chemotherapeutic challenge, consumption of a diet rich in DHA can slow tumor growth, prevent hyperlipidemia, enhance bone marrow cellularity, and promote intestinal growth compared with a moderate-fat n--6-rich diet.
Atkinson
T G
TG
Department of Human Biology and Nutritional Sciences, University of Guelph, ON, Canada.
Murray
L
L
Berry
D M
DM
Ruthig
D J
DJ
Meckling-Gill
K A
KA
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology; D002784:Cholesterol / Q000097:blood; D003561:Cytarabine / Q000627:therapeutic use*; D004042:Dietary Fats, Unsaturated / Q000627:therapeutic use*; D004281:Docosahexaenoic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D005227:Fatty Acids / Q000032:analysis; D005354:Fibrosarcoma / Q000150:complications* / Q000473:pathology / Q000628:therapy; D006949:Hyperlipidemias / Q000209:etiology / Q000517:prevention & control*; D007422:Intestines / Q000473:pathology; D008297:Male; D009929:Organ Size; D051381:Rats; D011916:Rats, Inbred F344; D012450:Safflower Oil / Q000008:administration & dosage; D014280:Triglycerides / Q000097:blood
D000964:Antimetabolites, Antineoplastic; D004042:Dietary Fats, Unsaturated; D005227:Fatty Acids; D014280:Triglycerides; D003561:Cytarabine; D004281:Docosahexaenoic Acids; D012450:Safflower Oil; D002784:Cholesterol